# V1 Empirics Check — google/gemini-3-flash-preview (Variant B)

**Model:** google/gemini-3-flash-preview
**Variant:** B
**Date:** 2026-03-25T15:08:12.006318

---

**Referee Report on "The Harmonization Illusion: EU Trade Secret Protection and Business R&D"**

### 1. Idea Fidelity
The paper follows the core premise of the original manifest: evaluating the impact of the EU Trade Secrets Directive (2016/943) on business R&D (BERD) using a staggered DiD framework. It correctly identifies the transposition window and uses the NUTS2 regional data proposed. However, there are a few deviations and missed opportunities from the manifest:
*   **Data Scale:** The manifest projected a sample of 431 NUTS2 regions (~3,251 observations). The paper uses a much-reduced balanced panel of only 83 regions (~1,162 observations). This significantly reduces the statistical power and geographic representativeness originally envisioned.
*   **Secondary Outcomes:** The manifest suggested looking at manufacturing value added, high-tech exports, and firm births. The paper ignores these, focusing almost exclusively on BERD/GDP. 
*   **Identification Detail:** The manifest suggested using "country-year trends" and "ECB MFI lending rates" as controls; these are absent from the paper's specification, which relies on a more parsimonious FE structure.

### 2. Summary
This paper investigates the causal effect of the 2016 EU Trade Secrets Directive on business R&D intensity across European regions. Utilizing the staggered transposition of the Directive (2018–2019) and a Callaway–Sant’Anna estimator, the author finds a precisely estimated null effect on R&D spending. The study suggests that legal harmonization may be a non-binding constraint for firms that already utilize private substitutes for intellectual property protection.

### 3. Essential Points
1.  **Sample Selection and Generalizability:** The drop from the 431 available NUTS2 regions to 83 for the sake of a "strictly balanced panel" is a major concern. R\&D data is notoriously patchy in Eurostat, but by discarding nearly 80% of the sample, the author likely excludes the "low protection" Eastern European regions where the "treatment dose" was highest (as these often have skip-pattern reporting). This potentially biases the result toward a null by over-representing stable, high-innovation Western European regions. The Sun-Abraham results on the unbalanced panel (N=2,107) are mentioned but not fully explored as the primary specification.
2.  **Transposition vs. Adoption Timing:** The Directive was adopted in 2016 with a clear 2018 deadline. Rational firms likely anticipated the legal change. The "Post" indicator starts at the transposition date (2018/2019), but investment decisions for 2018/2019 were likely made in 2016/2017. The paper needs to address this anticipatory behavior more rigorously, perhaps by testing for effects immediately following the 2016 adoption.
3.  **Measurement of Treatment Intensity:** The "Heterogeneity" table is a critical part of the argument but is currently underdeveloped. Table 5 shows a large negative and significant coefficient for "High Protection" countries (-0.237, SE 0.063) and a positive point estimate for "Low Protection." This contradicts the "overall null" narrative. If the Directive actually *reduced* R&D in high-protection countries (perhaps due to compliance costs or legal uncertainty during the transition), that is a major finding that the "Harmonization Illusion" title ignores.

### 4. Suggestions
*   **Expand the Sample:** Move the Sun-Abraham (2021) or Wooldridge (2021) Mundlak-style estimator to the forefront to include the full unbalanced panel of 431 regions. A "balanced panel" requirement is too restrictive for Eurostat NUTS2 data and compromises the study's ability to see the effect in the most "treated" jurisdictions.
*   **Mechanism Testing:** To support the "Private Substitutes" argument, the author could use the Community Innovation Survey (CIS) data (if accessible) or secondary indicators to see if firms in these regions increased spending on "Internal Security" or "Legal Services" relative to R&D.
*   **Refine the Heterogeneity Analysis:** The manifest mentioned Baker McKenzie (2016) surveys. The paper should use a more continuous "Distance to Directive" measure based on specific legal gaps identified in that survey (e.g., "Lack of definition" = 3 points, "Lack of injunctions" = 5 points) rather than three broad tiers.
*   **Address "Never-Treated" Paradox:** The paper classifies countries that had pre-existing laws (like Czechia) as "never-treated." However, the Directive also implemented *litigation confidentiality*, which was new even for many high-protection countries. The author should verify if these "never-treated" countries truly experienced zero legal change.
*   **Industry Composition:** R&D intensity varies by industry. The null effect might mask a reallocation of R&D from patent-intensive sectors (pharmaceuticals) to secrecy-intensive sectors (software/algorithms). Controlling for regional industrial structure (NACE 2-digit employment shares) would add robustness.
*   **Visualization:** An event-study plot is essential for an AER: Insights style paper. While the coefficients are listed in the text, a figure showing the pre-trends and post-treatment path (split by "Low" vs "High" protection) would be more convincing than Table 4.
*   **Clarify Table 5:** The coefficient for High Protection (-0.237) is huge—nearly half of the pre-treatment mean. This suggests either a data error, a coding issue with the transposition dates, or a very interesting negative effect that deserves more than a "suggestive gradient" label.
*   **Lending Rates:** Use the ECB MFI lending rates (mentioned in the manifest but omitted) as a control for the cost of capital, which was changing significantly during this period (end of QE, etc.) and could confound R&D trends.
